Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy

  • STATUS
    Recruiting
  • End date
    Aug 30, 2023
  • participants needed
    40
  • sponsor
    Zealand University Hospital
Updated on 19 July 2021

Summary

This protocol describes a phase II trial investigating the efficacy of CBD in paclitaxel- and oxaliplatin-induced peripheral neuropathy. The trial uses multiple assessments such as validated PRO-questionnaires and multifrequency vibrometry.

Description

Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to omission or even discontinuation of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.

Details
Condition Chemotherapy Induced Peripheral Neuropathy
Treatment Cannabidiol 100 MG/ML
Clinical Study IdentifierNCT04582591
SponsorZealand University Hospital
Last Modified on19 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

years of age
A diagnosis of cancer
Fulfill criteria for starting chemotherapy
Scheduled to undergo at least 6 courses of paclitaxel or 4 courses of oxaliplatin based chemotherapy
If not postmenopausal (defined as no menses for 12 months without an alternative medical cause), women will have use effective anti-contraception (using definitions in the CTFG-Recommendations related to contraception and pregnancy testing in clinical trials) and submit to a monthly pregnancy test (blood test)

Exclusion Criteria

Unable to complete PRO-measurements
Previously received taxanes or platinum-based chemotherapy
If using any antiepileptic or antidepressant medicine (ATC: N03A or N06A). Treatment must be stable (no changes in dosing in last 30 days) prior to inclusion. However, any treatment with Clobazam (N05BA09) is not allowed due to major interaction with cannabidiol
Use of cannabinoids. If in use, treatment must be stopped 4 days prior to inclusion
Hypersensitivity reactions towards Ascorbylpalmitat or Triglycerides (medium-chain)
Baseline transaminase level must not be above 3 times the Upper Limit of Normal (ULN) at study beginning
Women who are breastfeeding
Concomitant treatment with strong inducers of CYP3A4 and/or strong inducers of CYP2C19
CTFG: The Heads of Medicines Agencies commissioned Clinical Trials
Facilitation Group under the European Union's clinical trials directive
20
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note